Ausgabe 11/2014
Inhalt (31 Artikel)
Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals
C. Decristoforo, I. Penuelas, P. Elsinga, J. Ballinger, A. D. Winhorst, A. Verbruggen, F. Verzijlbergen, A. Chiti
Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma
Charles Lemarignier, Frédéric Di Fiore, Charline Marre, Sébastien Hapdey, Romain Modzelewski, Pierrick Gouel, Pierre Michel, Bernard Dubray, Pierre Vera
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma
Myriam Sasanelli, Michel Meignan, Corinne Haioun, Alina Berriolo-Riedinger, René-Olivier Casasnovas, Alberto Biggi, Andrea Gallamini, Barry A. Siegel, Amanda F. Cashen, Pierre Véra, Hervé Tilly, Annibale Versari, Emmanuel Itti
Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma
Jean François Grellier, Laetitia Vercellino, Thierry Leblanc, Pascal Merlet, Catherine Thieblemont, Pierre Weinmann, Marie-Elisabeth Toubert, Nathalie Berenger, Josette Brière, Pauline Brice
Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma
Jun Sato, Yoshimasa Kitagawa, Yutaka Yamazaki, Hironobu Hata, Takuya Asaka, Masaaki Miyakoshi, Shozo Okamoto, Tohru Shiga, Masanobu Shindoh, Yuji Kuge, Nagara Tamaki
Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy
Gaber Komar, Kaisa Lehtiö, Marko Seppänen, Olli Eskola, Helena Levola, Paula Lindholm, Hannu Sipilä, Jan Seppälä, Reidar Grénman, Olof Solin, Heikki Minn
Metabolic parameters using 18F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma
Do-Hoon Kim, Bong-Il Song, Chae Moon Hong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn
Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
Carlos Caicedo, Maria Jose Garcia-Velloso, Maria Dolores Lozano, Tania Labiano, Carmen Vigil Diaz, Jose Maria Lopez-Picazo, Alfonso Gurpide, Javier Zulueta, Jose Angel Richter Echevarria, Jose Luis Perez Gracia
Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients
Satoshi Takeuchi, Aparna Balachandran, Mouhammed Amir Habra, Alexandria T. Phan, Roland L. Bassett Jr., Homer A. Macapinlac, Hubert H. Chuang
Furosemide diminishes 18F-fluoroethylcholine uptake in prostate cancer in vivo
H. Christian Rischke, Teresa Beck, Werner Vach, Gesche Wieser, Anca L. Grosu, Wolfgang Schultze-Seemann, Philipp T. Meyer, Cordula A. Jilg
18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study
Luka Lezaic, Sebastijan Rep, Mojca Jensterle Sever, Tomaz Kocjan, Marko Hocevar, Jure Fettich
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging
Laura Gilardi, Chiara Maria Grana, Giovanni Paganelli
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
Neeta Pandit-Taskar, Joseph A. O’Donoghue, Volkan Beylergil, Serge Lyashchenko, Shutian Ruan, Stephen B. Solomon, Jeremy C. Durack, Jorge A. Carrasquillo, Robert A. Lefkowitz, Mithat Gonen, Jason S. Lewis, Jason P. Holland, Sarah M. Cheal, Victor E. Reuter, Joseph R. Osborne, Massimo F. Loda, Peter M. Smith-Jones, Wolfgang A. Weber, Neil H. Bander, Howard I. Scher, Michael J. Morris, Steven M. Larson
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
C. Kratochwil, F. L. Giesel, F. Bruchertseifer, W. Mier, C. Apostolidis, R. Boll, K. Murphy, U. Haberkorn, A. Morgenstern
Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients
IL Han Choo, Stephen F. Carter, Michael L. Schöll, Agneta Nordberg
Comparing amyloid-β deposition, neuroinflammation, glucose metabolism, and mitochondrial complex I activity in brain: a PET study in aged monkeys
Hideo Tsukada, Shingo Nishiyama, Hiroyuki Ohba, Masakatsu Kanazawa, Takeharu Kakiuchi, Norihiro Harada
Do CSF levels of t-Tau, p-Tau and β1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease
Agostino Chiaravalloti, Alessandro Stefani, Alessandro Fiorentini, Annamaria Lacanfora, Paolo Stanzione, Orazio Schillaci
The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition
K. Herholz, R. Evans, J. Anton-Rodriguez, R. Hinz, J. C. Matthews
Molecular imaging: the emerging role of optical imaging in nuclear medicine
Fijs W. B. van Leeuwen, Marion de Jong
Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology
Eric Laffon, Roger Marthan
Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan
Dirk Hasenclever, Lars Kurch, Regine Kluge
FDG PET/CT methodology for evaluation of treatment response in lymphoma: from “graded visual analysis” and “semiquantitative SUVmax” to global disease burden assessment
Sandip Basu, Habib Zaidi, Ali Salavati, Søren Hess, Poul Flemming Høilund Carlsen, Abass Alavi
Paolo Pozzilli, Andrea Lenzi, Bart L. Clarke, William F. Young Jr. (Eds): Imaging in Endocrinology
Manuela Amato, Luigi Mansi
Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
Carlos Caicedo, Maria Jose Garcia-Velloso, Maria Dolores Lozano, Tania Labiano, Carmen Vigil-Diaz, Jose Maria Lopez-Picazo, Alfonso Gurpide, Javier J. Zulueta, Jose Angel Richter-Echevarria, Jose Luis Perez-Gracia
Erratum to: Do CSF levels of t-Tau, p-Tau and β1–42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease
Agostino Chiaravalloti, Alessandro Stefani, Alessandro Fiorentini, Annamaria Lacanfora, Paolo Stanzione, Orazio Schillaci
Widespread vascular inflammation in a patient with antineutrophil cytoplasmic antibody-associated vasculitis as detected by positron emission tomography
Soile P. Salomäki, Jukka Kemppainen, Heikki Aho, Ulla Hohenthal, Renate Kain, Niina Koivuviita, Robert M. Badeau, Marko Seppänen, Antti Silvoniemi, Anne Roivainen, Laura Pirilä
Ideas from the second UEMS conference on CME/CPD: new EU directives on a patients’ rights in cross-border healthcare and professional qualifications
Teresio Varetto, Durval C. Costa
EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
Sergio Todde, Albert D. Windhorst, Martin Behe, Guy Bormans, Clemens Decristoforo, Alain Faivre-Chauvet, Valentina Ferrari, Antony D. Gee, Balazs Gulyas, Christer Halldin, Petra Kolenc Peitl, Jacek Koziorowski, Thomas L. Mindt, Martina Sollini, Johnny Vercouillie, James R. Ballinger, Philip H. Elsinga